The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KISUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanemab, from its inception to its game-changing approval.
The Birth of a Breakthrough
Eli Lilly’s donanemab is a monoclonal antibody specifically designed to target amyloid-beta plaques in the brain, which are strongly associated with Alzheimer’s disease. This innovative approach aims to slow the progression of cognitive decline in patients with early sympt...